Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $11.6 million.

  • Aytu Biopharma's Operating Expenses fell 710.68% to $11.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $50.5 million, marking a year-over-year decrease of 26.24%. This contributed to the annual value of $53.7 million for FY2025, which is 594.93% up from last year.
  • Latest data reveals that Aytu Biopharma reported Operating Expenses of $11.6 million as of Q4 2025, which was down 710.68% from $10.7 million recorded in Q3 2025.
  • Over the past 5 years, Aytu Biopharma's Operating Expenses peaked at $66.1 million during Q1 2022, and registered a low of $10.4 million during Q1 2025.
  • Over the past 5 years, Aytu Biopharma's median Operating Expenses value was $18.1 million (recorded in 2023), while the average stood at $21.6 million.
  • As far as peak fluctuations go, Aytu Biopharma's Operating Expenses soared by 20855.23% in 2021, and later tumbled by 6777.8% in 2023.
  • Aytu Biopharma's Operating Expenses (Quarter) stood at $23.6 million in 2021, then increased by 2.41% to $24.2 million in 2022, then plummeted by 52.58% to $11.5 million in 2023, then rose by 8.94% to $12.5 million in 2024, then decreased by 7.11% to $11.6 million in 2025.
  • Its Operating Expenses stands at $11.6 million for Q4 2025, versus $10.7 million for Q3 2025 and $17.9 million for Q2 2025.